Christina I. Stahre

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial).

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial).

Journal: PloS one

Published: July 06, 2021

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.

Journal: JAMA cardiology

Published: December 08, 2017

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: January 11, 2017

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.

Journal: Diabetes, obesity & metabolism

Published: December 04, 2016

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Journal: Diabetes care

Published: March 21, 2016

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: February 12, 2016

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.

Journal: Diabetes care

Published: December 21, 2015

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Journal: Diabetes care

Published: May 20, 2015

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.

Journal: Diabetes care

Published: December 02, 2014

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.

Journal: Diabetes care

Published: June 11, 2014

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.

Journal: Diabetes/metabolism research and reviews

Published: March 18, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026